Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Ocular Therapeutix Inc (NASDAQ: OCUL) was $8.40 for the day, down -0.36% from the previous closing price of $8.43. In other words, the price has decreased by -$0.36 from its previous closing price. On the day, 2.72 million shares were traded. OCUL stock price reached its highest trading level at $8.68 during the session, while it also had its lowest trading level at $8.3.
Ratios:
Our analysis of OCUL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 21.29 and its Current Ratio is at 21.39. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, TD Cowen on June 20, 2024, Upgraded its rating to Buy and sets its target price to $11 from $7 previously.
On February 09, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $15.BofA Securities initiated its Buy rating on February 09, 2024, with a $15 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 23 ’24 when Dugel Pravin sold 21,626 shares for $5.79 per share. The transaction valued at 125,215 led to the insider holds 833,353 shares of the business.
Nayak Sanjay sold 2,274 shares of OCUL for $13,280 on May 23 ’24. The Chief Strategy Officer now owns 178,026 shares after completing the transaction at $5.84 per share. On Feb 26 ’24, another insider, SUMMER ROAD LLC, who serves as the 10% Owner of the company, bought 930,851 shares for $7.52 each. As a result, the insider paid 7,000,000 and bolstered with 8,591,401 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1301067520 and an Enterprise Value of 892583872. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.74 while its Price-to-Book (P/B) ratio in mrq is 3.19. Its current Enterprise Value per Revenue stands at 14.915 whereas that against EBITDA is -10.14.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.31, which has changed by 0.7948718 over the last 52 weeks, in comparison to a change of 0.24125004 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $11.31, while it has fallen to a 52-week low of $2.00. The 50-Day Moving Average of the stock is 37.86%, while the 200-Day Moving Average is calculated to be 54.31%.
Shares Statistics:
OCUL traded an average of 2.73M shares per day over the past three months and 1802460 shares per day over the past ten days. A total of 154.89M shares are outstanding, with a floating share count of 134.69M. Insiders hold about 13.04% of the company’s shares, while institutions hold 68.68% stake in the company. Shares short for OCUL as of 1719532800 were 21339425 with a Short Ratio of 7.83, compared to 1717113600 on 22473946. Therefore, it implies a Short% of Shares Outstanding of 21339425 and a Short% of Float of 13.83.
